Development of a solidified self-microemulsifying drug delivery system (S-SMEDDS) for atorvastatin calcium with improved dissolution and bioavailability.

Dong Woo Yeom, Ho Yong Son, Jin Han Kim, Sung Rae Kim, Sang Gon Lee, She Hyon Song, Bo Ram Chae, Young Wook Choi
Author Information
  1. Dong Woo Yeom: College of Pharmacy, Chung-Ang University, 84 Heuksuk-ro, Dongjak-gu, Seoul 06974, Republic of Korea. Electronic address: yeompd@naver.com.
  2. Ho Yong Son: College of Pharmacy, Chung-Ang University, 84 Heuksuk-ro, Dongjak-gu, Seoul 06974, Republic of Korea. Electronic address: lakers0204@naver.com.
  3. Jin Han Kim: College of Pharmacy, Chung-Ang University, 84 Heuksuk-ro, Dongjak-gu, Seoul 06974, Republic of Korea. Electronic address: jinhan8910@daum.net.
  4. Sung Rae Kim: College of Pharmacy, Chung-Ang University, 84 Heuksuk-ro, Dongjak-gu, Seoul 06974, Republic of Korea. Electronic address: kimsrkr@naver.com.
  5. Sang Gon Lee: College of Pharmacy, Chung-Ang University, 84 Heuksuk-ro, Dongjak-gu, Seoul 06974, Republic of Korea. Electronic address: idealgon@gmail.com.
  6. She Hyon Song: Daewon Pharm. Co., Ltd., 520 Cheonhodae-ro, Gwangjin-gu, Seoul 04994, Republic of Korea. Electronic address: 208058@daewonpharm.com.
  7. Bo Ram Chae: Daewon Pharm. Co., Ltd., 520 Cheonhodae-ro, Gwangjin-gu, Seoul 04994, Republic of Korea. Electronic address: hifyram@daewonpharm.com.
  8. Young Wook Choi: College of Pharmacy, Chung-Ang University, 84 Heuksuk-ro, Dongjak-gu, Seoul 06974, Republic of Korea. Electronic address: ywchoi@cau.ac.kr.

Abstract

To improve the dissolution and oral bioavailability (BA) of atorvastatin calcium (ATV), we previously introduced an optimized self-microemulsifying drug delivery system (SMEDDS) using Capmul(®) MCM (oil), Tween(®) 20 (surfactant), and tetraglycol (cosurfactant). In this study, various solid carriers were employed to develop a solidified SMEDDS (S-SMEDDS): mannitol (M) and lactose (L) as water-soluble carriers, and Sylysia(®) 350 (S) and Aerosil(®) 200 (A) as water-insoluble carriers. Maximum solidifying capacities (SCmax) of water-insoluble carriers were significantly greater than those of water-soluble carriers were. The resultant powders were free flowing with an angle of repose <40° and Carr's index 5-20%, regardless of the solid carrier types. S-SMEDDS with mannitol (S(M)-SMEDDS) or lactose (S(L)-SMEDDS) had a smaller droplet size and greater dissolution than S-SMEDDS with Sylysia(®) 350 (S(S)-SMEDDS) or Aerosil(®) 200 (S(A)-SMEDDS). Following oral administration of various formulations to rats at a dose equivalent to 25mg/kg of ATV, plasma drug levels were measured by LC-MS/MS. The relative BAs (RBAs) of SMEDDS, S(M)-SMEDDS, and S(S)-SMEDDS were 345%, 216%, and 160%, respectively, compared to that of ATV suspension. Additionally, at a reduced dose of ATV equivalent to 5mg/kg, the RBAs of S(M)-SMEDDS and S(S)-SMEDDS compared to that of SMEDDS were 101% and 65%, respectively. These results suggest that S(M)-SEMDDS offers great potential for the development of solid dosage forms with improved oral absorption of drugs with poor water solubility.

Keywords

MeSH Term

Administration, Oral
Animals
Anticholesteremic Agents
Atorvastatin
Biological Availability
Chemistry, Pharmaceutical
Chromatography, Liquid
Dose-Response Relationship, Drug
Drug Carriers
Drug Delivery Systems
Emulsions
Excipients
Male
Particle Size
Rats
Rats, Sprague-Dawley
Solubility
Surface-Active Agents
Tandem Mass Spectrometry

Chemicals

Anticholesteremic Agents
Drug Carriers
Emulsions
Excipients
Surface-Active Agents
Atorvastatin

Word Cloud

Created with Highcharts 10.0.0S-SMEDDS®SMEDDScarriersMATVS-SMEDDSdissolutionoraldrugsolidSylysia350bioavailabilityatorvastatincalciumself-microemulsifyingdeliverysystemvarioussolidifiedmannitollactoseLwater-solubleAerosil200water-insolublegreatercarrierdoseequivalentRBAsrespectivelycomparedimprovedimproveBApreviouslyintroducedoptimizedusingCapmulMCMoilTween20surfactanttetraglycolcosurfactantstudyemployeddevelop:MaximumsolidifyingcapacitiesSCmaxsignificantlyresultantpowdersfreeflowinganglerepose<40°Carr'sindex5-20%regardlesstypessmallerdropletsizeFollowingadministrationformulationsrats25mg/kgplasmalevelsmeasuredLC-MS/MSrelativeBAs345%216%160%suspensionAdditionallyreduced5mg/kg101%65%resultssuggest-SEMDDSoffersgreatpotentialdevelopmentdosageformsabsorptiondrugspoorwatersolubilityDevelopmentAtorvastatinMannitolSolidSolidified

Similar Articles

Cited By